Vagal Autonomic Stimulation Physiotherapy (With Trigger Point Release) as an Adjunct to Personalized Antihypertensive Management of Gestational Hypertension Syndrome and Preeclampsia
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 210
- 试验地点
- 12
- 主要终点
- Changes in participants' blood pressure from baseline (T0), every 2 weeks (T1, T2, T3...), until the end of the evaluation period (TX).
研究概览
简要总结
Preeclampsia is one of the most common and serious complications of pregnancy, affecting both the mother and baby. It is a condition characterized by high blood pressure and can lead to severe complications, including neurological issues and reduced blood flow to the placenta. Preeclampsia is responsible for a significant number of maternal and perinatal deaths worldwide, with an estimated 14% of maternal mortality in Mexico linked to this condition.
Recent research suggests that disruptions in the body's autonomic nervous system, specifically the balance between the sympathetic and parasympathetic systems, play a role in the development of preeclampsia. The vagus nerve, which is part of the parasympathetic system, has been shown to regulate inflammation and blood pressure. Stimulating this nerve through pharmacological, magnetic, electrical, or physical therapy techniques has shown promise in preclinical models for improving blood pressure control and reducing complications associated with preeclampsia.
Trigger point release therapy modulates the nervous system by reducing sympathetic activity, promoting blood vessel relaxation, lowering heart rate, and enhancing circulation. When combined with standard antihypertensive treatment, this approach may offer additional benefits for blood pressure regulation.
This study aims to evaluate the effects of vagal autonomic stimulation physiotherapy using trigger point release therapy as a complementary treatment for pregnant women with preeclampsia. Participants will be randomly assigned to receive either standard antihypertensive treatment with positional release therapy (control group) or the same treatment combined with vagal stimulation physiotherapy (intervention group). Researchers will assess the intervention's effectiveness in controlling blood pressure and improving overall maternal and fetal health outcomes.
By investigating this non-invasive, drug-free approach, this study aims to offer new strategies for managing preeclampsia, potentially improving maternal and fetal health while reducing reliance on medication.
详细描述
Among hypertensive disorders of pregnancy, preeclampsia is the most common medical complication and is associated with high medical and social costs, making it a significant public health concern.
Although its global prevalence is unknown, preeclampsia is implicated in 14% of maternal deaths worldwide. In Mexico, it accounts for approximately 14% of maternal mortality, corresponding to a rate of 30.4 per 100,000 live births, and 17.2% of total perinatal deaths. Of these maternal deaths, 30% to 70% result from neurological complications where cerebral autoregulation is lost, leading to vasospasm, reduced blood flow, and ischemic and infarcted areas in the placenta.
Recent evidence suggests that dysregulation of the cholinergic anti-inflammatory pathway (CAP) may contribute to preeclampsia development. This pathway connects the central nervous system-via the vagus nerve-to mechanisms regulating inflammation in the body. It is influenced by the downregulation of the α7 nicotinic acetylcholine receptor, which has been associated with systemic inflammation in preeclampsia. Additionally, some electrical, pharmacological, magnetic, and physical vagal stimulation techniques targeting this pathway have shown promising results in preclinical models of preeclampsia, making vagus nerve activation a potential strategy for managing this pregnancy complication. Clinically, various vagal stimulation techniques, such as deep breathing, progressive relaxation, and transcranial magnetic stimulation, have been approved for treating depression and epilepsy in pregnant women.
Primarily linked to the parasympathetic nervous system, the vagus nerve is also influenced by the sympathetic nervous system through peripheral receptors. Trigger point stimulation therapy in physiotherapy can block sympathetic nervous system activity, reducing peripheral vascular resistance, venous return, heart rate, and myocardial contractility by promoting systemic arterial and venous vasodilation. In this context, physiotherapy involving trigger point release could serve as an adjunct treatment for blood pressure control in preeclamptic patients by modulating the peripheral nervous system. However, its impact on autonomic tone has not yet been reported.
This study aims to explore the benefits of vagal stimulation through trigger point release, combined with medical treatment for preeclampsia-an approach that has not been fully investigated in our setting. This protocol presents a non-invasive complementary technique to support personalized pharmacological management of preeclamptic patients. By enhancing the vasorelaxant response derived from autonomic nervous system activity, this intervention may help reduce blood pressure levels and biochemical markers associated with preeclampsia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
盲法说明
The study is designed as a double-blind, non-pharmacological clinical trial with a pre-test/post-test design. Both the participants and the outcome evaluator conducting the statistical analysis will be blinded.
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Outpatient female patients over 18 years old, attending their first appointment and seen in the obstetrics outpatient clinic at the Regional General Hospitals of IMSS Jalisco, with a pregnancy complicated by confirmed mild preeclampsia.
- •No prior treatment.
- •Willing to participate by signing an informed consent form.
排除标准
- •Patients with chronic hypertension.
- •Concomitant organ dysfunction.
- •Immunological diseases.
- •Patients with severe preeclampsia or chronic conditions concomitant with pregnancy.
- •Patients with gestational trophoblastic disease requiring uterine evacuation or choriocarcinoma associated with hypertension.
研究组 & 干预措施
Vagal Stimulation Physiotherapy with Trigger Point Release (TEV Group).
Administration of physiotherapy sessions for vagal stimulation with trigger point release, in addition to personalized antihypertensive treatment.
干预措施: Vagal stimulation physiotherapy with trigger point release (Other)
Positional Release Therapy (TLP Group).
Administration of positional release therapy sessions, in addition to personalized antihypertensive treatment.
干预措施: Positional Release Therapy (Other)
结局指标
主要结局
Changes in participants' blood pressure from baseline (T0), every 2 weeks (T1, T2, T3...), until the end of the evaluation period (TX).
时间窗: From baseline until weeks 4 to 5 after obstetric resolution.
Observed changes in the measurement of participants' diastolic and systolic blood pressure, recorded at baseline (T0), every 2 weeks (T1, T2, T3...), until the end of the evaluation period (TX).
Changes in participants' heart rate from baseline (T0), every 2 weeks (T1, T2, T3...), until the end of the evaluation period (TX).
时间窗: From baseline until weeks 4 to 5 after obstetric resolution.
Observed changes in the measurement of participants' heart rate, recorded at baseline (T0), every 2 weeks (T1, T2, T3...), until the end of the evaluation period (TX).
次要结局
- Biochemical parameters of renal function (Changes in serum creatinine levels in the participants)(From baseline until 4 to 5 weeks after obstetric resolution.)
- Biochemical parameters of renal function (Changes in serum Urea levels in the participants)(From baseline until 4 to 5 weeks after obstetric resolution.)
- Biochemical parameters of renal function (Changes in serum uric acid levels in the participants)(From baseline until 4 to 5 weeks after obstetric resolution.)
- Biochemical parameters of renal function (Changes in Glomerular filtration rate in the participants)(From baseline until 4 to 5 weeks after obstetric resolution.)
- Hematological parameters (Changes in complete blood count with platelet count in the participants)(From baseline until 4 to 5 weeks after obstetric resolution.)
- Biochemical parameters of hepatic function (Changes in serum aspartate aminotransferase levels in the participants)(From baseline until 4 to 5 weeks after obstetric resolution.)
- Biochemical parameters of hepatic function (Changes in serum alanine aminotransferase levels in the participants)(From baseline until 4 to 5 weeks after obstetric resolution.)
- Biochemical parameters of hepatic function (Changes in serum lactate dehydrogenase levels in the participants)(From baseline until 4 to 5 weeks after obstetric resolution.)
- Biochemical parameters of hepatic function (Changes in serum gamma-glutamyl transferase levels in the participants)(From baseline until 4 to 5 weeks after obstetric resolution.)
- Biochemical parameters of hepatic function (Changes in serum total protein levels in the participants)(From baseline until 4 to 5 weeks after obstetric resolution.)
- Biochemical parameters of hepatic function (Changes in serum albumin levels in the participants)(From baseline until 4 to 5 weeks after obstetric resolution.)
- Biochemical parameters of hepatic function (Changes in serum globulin levels in the participants)(From baseline until 4 to 5 weeks after obstetric resolution.)
- Biochemical parameters of hepatic function (Changes in serum albumin/globulin ratio in the participants)(From baseline until 4 to 5 weeks after obstetric resolution.)
- Biochemical parameters of hepatic function (Changes in serum total cholesterol levels in the participants)(From baseline until 4 to 5 weeks after obstetric resolution.)
- Biochemical parameters of hepatic function (Changes in serum HDL cholesterol levels in the participants)(From baseline until 4 to 5 weeks after obstetric resolution.)
- Biochemical parameters of hepatic function (Changes in serum LDL cholesterol levels in the participants)(From baseline until 4 to 5 weeks after obstetric resolution.)
- Biochemical parameters of hepatic function (Changes in serum VLDL cholesterol levels in the participants)(From baseline until 4 to 5 weeks after obstetric resolution.)
- Biochemical parameters of hepatic function (Changes in serum triglyceride levels in the participants)(From baseline until 4 to 5 weeks after obstetric resolution.)
- Biochemical Parameters of Inflammatory and Endothelial Dysfunction Response (Changes in serum C-reactive protein levels in the participants)(From baseline until 4 to 5 weeks after obstetric resolution.)
- Biochemical Parameters of Inflammatory and Endothelial Dysfunction Response (Changes in serum D-dimer levels in the participants)(From baseline until 4 to 5 weeks after obstetric resolution.)
- Biochemical Parameters of Inflammatory and Endothelial Dysfunction Response (Changes in prothrombin time in the participants)(From baseline until 4 to 5 weeks after obstetric resolution.)
- Biochemical Parameters of Inflammatory and Endothelial Dysfunction Response (Changes in activated partial thromboplastin time in the participants)(From baseline until 4 to 5 weeks after obstetric resolution.)
研究者
Carlos Alberto Garcia Becerra, MD, MSc
Principal Investigator, Fundación Internacional René Mey
Fundación Internacional René Mey